{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:54:56Z","timestamp":1794048896475,"version":"4.8.0"},"reference-count":150,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T00:00:00Z","timestamp":1537315200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1038\/s41581-018-0059-6","type":"journal-article","created":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T15:51:09Z","timestamp":1537372269000},"page":"704-716","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":116,"title":["Renal disease in tuberous sclerosis complex: pathogenesis and therapy"],"prefix":"10.1038","volume":"14","author":[{"given":"Hilaire C.","family":"Lam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Siroky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth P.","family":"Henske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,19]]},"reference":[{"key":"59_CR1","doi-asserted-by":"crossref","first-page":"16035","DOI":"10.1038\/nrdp.2016.35","volume":"2","author":"EP Henske","year":"2016","unstructured":"Henske, E. P., Jozwiak, S., Kingswood, J. C., Sampson, J. R. & Thiele, E. A. Tuberous sclerosis complex. Nat. Rev. Dis. Primers 2, 16035 (2016).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"59_CR2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMra055323","volume":"355","author":"PB Crino","year":"2006","unstructured":"Crino, P. B., Nathanson, K. L. & Henske, E. P. The tuberous sclerosis complex. N. Engl. J. Med. 355, 1345\u20131356 (2006).","journal-title":"N. Engl. J. Med."},{"key":"59_CR3","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(08)61279-9","volume":"372","author":"P Curatolo","year":"2008","unstructured":"Curatolo, P., Bombardieri, R. & Jozwiak, S. Tuberous sclerosis. Lancet 372, 657\u2013668 (2008).","journal-title":"Lancet"},{"key":"59_CR4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.pediatrneurol.2013.08.002","volume":"49","author":"DA Krueger","year":"2013","unstructured":"Krueger, D. A. & Northrup, H. International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr. Neurol. 49, 255\u2013265 (2013).","journal-title":"Pediatr. Neurol."},{"key":"59_CR5","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0022-3468(96)90689-2","volume":"31","author":"FM Robertson","year":"1996","unstructured":"Robertson, F. M., Cendron, M., Klauber, G. T. & Harris, B. H. Renal cell carcinoma in association with tuberous sclerosis in children. J. Pediatr. Surg. 31, 729\u2013730 (1996).","journal-title":"J. Pediatr. Surg."},{"key":"59_CR6","first-page":"351","volume":"48","author":"S Kulkarni","year":"2000","unstructured":"Kulkarni, S., Uddar, M., Deshpande, S. G., Vaid, S. & Wadia, R. S. Renal cell carcinoma as significant manifestation of tuberous sclerosis complex. J. Assoc. Physicians India 48, 351\u2013353 (2000).","journal-title":"J. Assoc. Physicians India"},{"key":"59_CR7","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/PAS.0000000000000237","volume":"38","author":"P Yang","year":"2014","unstructured":"Yang, P. et al. Renal cell carcinoma in tuberous sclerosis complex. Am. J. Surg. Pathol. 38, 895\u2013909 (2014).","journal-title":"Am. J. Surg. Pathol."},{"key":"59_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1148\/58.1.1","volume":"58","author":"JF Holt","year":"1952","unstructured":"Holt, J. F. & Dickerson, W. W. The osseous lesions of tuberous sclerosis. Radiology 58, 1\u20138 (1952).","journal-title":"Radiology"},{"key":"59_CR9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00004836-199407000-00012","volume":"19","author":"K Hizawa","year":"1994","unstructured":"Hizawa, K. et al. Gastrointestinal involvement in tuberous sclerosis. Two case reports. J. Clin. Gastroenterol. 19, 46\u201349 (1994).","journal-title":"J. Clin. Gastroenterol."},{"key":"59_CR10","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1749-6632.1991.tb37749.x","volume":"615","author":"SR Gould","year":"1991","unstructured":"Gould, S. R. Hamartomatous rectal polyps are common in tuberous sclerosis. Ann. NY Acad. Sci. 615, 71\u201380 (1991).","journal-title":"Ann. NY Acad. Sci."},{"key":"59_CR11","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/0140-6736(92)90244-W","volume":"339","author":"S Jozwiak","year":"1992","unstructured":"Jozwiak, S., Michalowicz, R., Pedich, M. & Rajszys, P. Hepatic hamartoma in tuberous sclerosis. Lancet 339, 180 (1992).","journal-title":"Lancet"},{"key":"59_CR12","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1399-0004.2011.01805.x","volume":"82","author":"AM Larson","year":"2012","unstructured":"Larson, A. M. et al. Pancreatic neuroendocrine tumors in patients with tuberous sclerosis complex. Clin.\u00a0Genet. 82, 558\u2013563 (2012).","journal-title":"Clin. Genet."},{"key":"59_CR13","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s00261-012-9880-8","volume":"38","author":"JH Wang","year":"2013","unstructured":"Wang, J. H. et al. Multi-modality imaging findings of splenic hamartoma: a report of nine cases and review of the literature. Abdom. Imag. 38, 154\u2013162 (2013).","journal-title":"Abdom. Imag."},{"key":"59_CR14","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1464-410X.2004.05046.x","volume":"94","author":"FJ O\u2019Callaghan","year":"2004","unstructured":"O\u2019Callaghan, F. J., Noakes, M. J., Martyn, C. N. & Osborne, J. P. An epidemiological study of renal pathology in tuberous sclerosis complex. BJU Int. 94, 853\u2013857 (2004).","journal-title":"BJU Int."},{"key":"59_CR15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1749-6632.1991.tb37754.x","volume":"615","author":"JP Osborne","year":"1991","unstructured":"Osborne, J. P., Fryer, A. & Webb, D. Epidemiology of tuberous sclerosis. Ann. NY Acad. Sci. 615, 125\u2013127 (1991).","journal-title":"Ann. NY Acad. Sci."},{"key":"59_CR16","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1172\/JCI58709","volume":"122","author":"EP Henske","year":"2012","unstructured":"Henske, E. P. & McCormack, F. X. Lymphangioleiomyomatosis \u2014 a wolf in sheep\u2019s clothing. J. Clin. Invest. 122, 3807\u20133816 (2012).","journal-title":"J. Clin. Invest."},{"key":"59_CR17","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.ki.5001853","volume":"70","author":"SK Rakowski","year":"2006","unstructured":"Rakowski, S. K. et al. Renal manifestations of tuberous sclerosis complex: incidence, prognosis, and predictive factors. Kidney Int. 70, 1777\u20131782 (2006).","journal-title":"Kidney Int."},{"key":"59_CR18","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/gcc.2870130411","volume":"13","author":"EP Henske","year":"1995","unstructured":"Henske, E. P. et al. Loss of heterozygosity in the tuberous sclerosis (TSC2) region of chromosome band 16p13 occurs in sporadic as well as TSC-associated renal angiomyolipomas. Genes Chromosomes Cancer 13, 295\u2013298 (1995).","journal-title":"Genes Chromosomes Cancer"},{"key":"59_CR19","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1126\/science.277.5327.805","volume":"277","author":"M Slegtenhorst van","year":"1997","unstructured":"van Slegtenhorst, M. et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 277, 805\u2013808 (1997).","journal-title":"Science"},{"key":"59_CR20","first-page":"4766","volume":"58","author":"TL Plank","year":"1998","unstructured":"Plank, T. L., Yeung, R. S. & Henske, E. P. Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles. Cancer Res. 58, 4766\u20134770 (1998).","journal-title":"Cancer Res."},{"key":"59_CR21","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","volume":"168","author":"RA Saxton","year":"2017","unstructured":"Saxton, R. A. & Sabatini, D. M. mTOR signaling in growth, metabolism, and disease. Cell 168, 960\u2013976 (2017).","journal-title":"Cell"},{"key":"59_CR22","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.tcb.2015.06.002","volume":"25","author":"CC Dibble","year":"2015","unstructured":"Dibble, C. C. & Cantley, L. C. Regulation of mTORC1 by PI3K signaling. Trends Cell Biol. 25, 545\u2013555 (2015).","journal-title":"Trends Cell Biol."},{"key":"59_CR23","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1056\/NEJMcibr1406613","volume":"371","author":"DJ Kwiatkowski","year":"2014","unstructured":"Kwiatkowski, D. J. & Manning, B. D. Molecular basis of giant cells in tuberous sclerosis complex. N. Engl. J. Med. 371, 778\u2013780 (2014).","journal-title":"N. Engl. J. Med."},{"key":"59_CR24","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1093\/cercor\/bhv026","volume":"26","author":"K Im","year":"2016","unstructured":"Im, K. et al. Altered structural brain networks in tuberous sclerosis complex. Cereb. Cortex 26, 2046\u20132058 (2016).","journal-title":"Cereb. Cortex"},{"key":"59_CR25","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nature11310","volume":"488","author":"PT Tsai","year":"2012","unstructured":"Tsai, P. T. et al. Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice. Nature 488, 647\u2013651 (2012).","journal-title":"Nature"},{"key":"59_CR26","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1093\/hmg\/ddu597","volume":"24","author":"ME Tyburczy","year":"2015","unstructured":"Tyburczy, M. E. et al. A shower of second hit events as the cause of multifocal renal cell carcinoma in tuberous sclerosis complex. Hum. Mol. Genet. 24, 1836\u20131842 (2015).","journal-title":"Hum. Mol. Genet."},{"key":"59_CR27","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1093\/hmg\/6.12.2155","volume":"6","author":"AC Jones","year":"1997","unstructured":"Jones, A. C. et al. Molecular genetic and phenotypic analysis reveals differences between TSC1 and TSC2 associated familial and sporadic tuberous sclerosis. Hum. Mol. Genet. 6, 2155\u20132161 (1997).","journal-title":"Hum. Mol. Genet."},{"key":"59_CR28","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1086\/316951","volume":"68","author":"SL Dabora","year":"2001","unstructured":"Dabora, S. L. et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am. J. Hum. Genet. 68, 64\u201380 (2001).","journal-title":"Am. J. Hum. Genet."},{"key":"59_CR29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1005637","volume":"11","author":"ME Tyburczy","year":"2015","unstructured":"Tyburczy, M. E. et al. Mosaic and intronic mutations in TSC1\/TSC2 explain the majority of TSC patients with no mutation identified by conventional testing.PLOS Genet. 11, e1005637 (2015).","journal-title":"PLOS Genet."},{"key":"59_CR30","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1086\/302381","volume":"64","author":"AC Jones","year":"1999","unstructured":"Jones, A. C. et al. Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. Am. J. Hum. Genet. 64, 1305\u20131315 (1999).","journal-title":"Am. J. Hum. Genet."},{"key":"59_CR31","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/ejhg.2011.241","volume":"20","author":"AM Eeghen van","year":"2012","unstructured":"van Eeghen, A. M., Black, M. E., Pulsifer, M. B., Kwiatkowski, D. J. & Thiele, E. A. Genotype and cognitive phenotype of patients with tuberous sclerosis complex. Eur. J. Hum. Genet. 20, 510\u2013515 (2012).","journal-title":"Eur. J. Hum. Genet."},{"key":"59_CR32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.pediatrneurol.2014.10.004","volume":"52","author":"PJ Vries de","year":"2015","unstructured":"de Vries, P. J. et al. Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND checklist. Pediatr. Neurol. 52, 25\u201335 (2015).","journal-title":"Pediatr. Neurol."},{"key":"59_CR33","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1073\/pnas.0810790106","volume":"106","author":"JJ Yu","year":"2009","unstructured":"Yu, J. J. et al. Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc. Natl Acad. Sci. USA 106, 2635\u20132640 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"59_CR34","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","volume":"364","author":"FX McCormack","year":"2011","unstructured":"McCormack, F. X. et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N. Engl. J. Med. 364, 1595\u20131606 (2011).","journal-title":"N. Engl. J. Med."},{"key":"59_CR35","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00000478-199804000-00012","volume":"22","author":"TE Muir","year":"1998","unstructured":"Muir, T. E. et al. Micronodular pneumocyte hyperplasia. Am. J. Surg. Pathol. 22, 465\u2013472 (1998).","journal-title":"Am. J. Surg. Pathol."},{"key":"59_CR36","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/modpathol.2010.114","volume":"23","author":"T Hayashi","year":"2010","unstructured":"Hayashi, T. et al. Loss of heterozygosity on tuberous sclerosis complex genes in multifocal micronodular pneumocyte hyperplasia. Mod. Pathol. 23, 1251\u20131260 (2010).","journal-title":"Mod. Pathol."},{"key":"59_CR37","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0025-6196(12)61196-3","volume":"66","author":"CW Shepherd","year":"1991","unstructured":"Shepherd, C. W., Gomez, M. R., Lie, J. T. & Crowson, C. S. Causes of death in patients with tuberous sclerosis. Mayo Clin. Proc. 66, 792\u2013796 (1991).","journal-title":"Mayo Clin. Proc."},{"key":"59_CR38","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1053\/j.ajkd.2015.05.016","volume":"66","author":"MJ Eijkemans","year":"2015","unstructured":"Eijkemans, M. J. et al. Long-term follow-up assessing renal angiomyolipoma treatment patterns, morbidity, and mortality: an observational study in tuberous sclerosis complex patients in the Netherlands. Am. J. Kidney. Dis. 66, 638\u2013645 (2015).","journal-title":"Am. J. Kidney. Dis."},{"key":"59_CR39","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/0092-8674(93)90618-Z","volume":"75","author":"European Chromosome 16 Tuberous Sclerosis Consortium","year":"1993","unstructured":"European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 75, 1305\u20131315 (1993).","journal-title":"Cell"},{"key":"59_CR40","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","volume":"381","author":"JJ Bissler","year":"2013","unstructured":"Bissler, J. J. et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 381, 817\u2013824 (2013).","journal-title":"Lancet"},{"key":"59_CR41","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","volume":"358","author":"JJ Bissler","year":"2008","unstructured":"Bissler, J. J. et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N. Engl. J. Med. 358, 140\u2013151 (2008).","journal-title":"N. Engl. J. Med."},{"key":"59_CR42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023379","volume":"6","author":"SL Dabora","year":"2011","unstructured":"Dabora, S. L. et al. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF-D levels decrease. PLOS ONE 6, e23379 (2011).","journal-title":"PLOS ONE"},{"key":"59_CR43","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cmet.2014.01.001","volume":"19","author":"J Li","year":"2014","unstructured":"Li, J., Kim, S. G. & Blenis, J. Rapamycin: one drug, many effects. Cell Metab. 19, 373\u2013379 (2014).","journal-title":"Cell Metab."},{"key":"59_CR44","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1212\/WNL.0b013e3182815428","volume":"80","author":"DA Krueger","year":"2013","unstructured":"Krueger, D. A. et al. Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma. Neurology 80, 574\u2013580 (2013).","journal-title":"Neurology"},{"key":"59_CR45","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","volume":"363","author":"DA Krueger","year":"2010","unstructured":"Krueger, D. A. et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N. Engl. J. Med. 363, 1801\u20131811 (2010).","journal-title":"N. Engl. J. Med."},{"key":"59_CR46","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/ana.23960","volume":"74","author":"DA Krueger","year":"2013","unstructured":"Krueger, D. A. et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex.Ann. Neurol. 74, 679\u2013687 (2013).","journal-title":"Ann. Neurol."},{"key":"59_CR47","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1212\/WNL.0000000000003400","volume":"87","author":"DA Krueger","year":"2016","unstructured":"Krueger, D. A. et al. Long-term treatment of epilepsy with everolimus in tuberous sclerosis. Neurology 87, 2408\u20132415 (2016).","journal-title":"Neurology"},{"key":"59_CR48","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jpeds.2017.05.015","volume":"187","author":"BJ Siroky","year":"2017","unstructured":"Siroky, B. J. et al. Improvement in renal cystic disease of tuberous sclerosis complex after treatment with mammalian target of rapamycin inhibitor. J. Pediatr. 187, 318\u2013322.e2 (2017).","journal-title":"J. Pediatr."},{"key":"59_CR49","volume":"11","author":"DN Franz","year":"2016","unstructured":"Franz, D. N. et al. Long-term use of everolimus in patients with tuberous sclerosis complex: final results from the EXIST-1 study. PLOS ONE 11, e0158476 (2016).","journal-title":"PLOS ONE"},{"key":"59_CR50","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","volume":"388","author":"JA French","year":"2016","unstructured":"French, J. A. et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet 388, 2153\u20132163 (2016).","journal-title":"Lancet"},{"key":"59_CR51","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/dmcn.13352","volume":"59","author":"S Amin","year":"2017","unstructured":"Amin, S. et al. Causes of mortality in individuals with tuberous sclerosis complex. Dev. Med. Child Neurol. 59, 612\u2013617 (2017).","journal-title":"Dev. Med. Child Neurol."},{"key":"59_CR52","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0022-5347(01)63072-6","volume":"160","author":"DH Ewalt","year":"1998","unstructured":"Ewalt, D. H., Sheffield, E., Sparagana, S. P., Delgado, M. R. & Roach, E. S. Renal lesion growth in children with tuberous sclerosis complex. J. Urol. 160, 141\u2013145 (1998).","journal-title":"J. Urol."},{"key":"59_CR53","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1097\/PAS.0000000000000248","volume":"38","author":"J Guo","year":"2014","unstructured":"Guo, J. et al. Tuberous sclerosis-associated renal cell carcinoma: a clinicopathologic study of 57 separate carcinomas in 18 patients. Am. J. Surg. Pathol. 38, 1457\u20131467 (2014).","journal-title":"Am. J. Surg. Pathol."},{"key":"59_CR54","first-page":"400","volume":"59","author":"EP Henske","year":"1996","unstructured":"Henske, E. P. et al. Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. Am. J. Hum. Genet. 59, 400\u2013406 (1996).","journal-title":"Am. J. Hum. Genet."},{"key":"59_CR55","first-page":"1639","volume":"151","author":"EP Henske","year":"1997","unstructured":"Henske, E. P. et al. Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the pathogenesis of tuberous sclerosis tumors. Am. J. Pathol. 151, 1639\u20131647 (1997).","journal-title":"Am. J. Pathol."},{"key":"59_CR56","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0002-9440(10)63843-6","volume":"162","author":"M Karbowniczek","year":"2003","unstructured":"Karbowniczek, M., Yu, J. & Henske, E. P. Renal angiomyolipomas from patients with sporadic lymphangiomyomatosis contain both neoplastic and non-neoplastic vascular structures. Am. J. Pathol. 162, 491\u2013500 (2003).","journal-title":"Am. J. Pathol."},{"key":"59_CR57","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3389\/fcell.2014.00069","volume":"2","author":"SP Delaney","year":"2014","unstructured":"Delaney, S. P., Julian, L. M. & Stanford, W. L. The neural crest lineage as a driver of disease heterogeneity in tuberous sclerosis complex and lymphangioleiomyomatosis. Front. Cell Dev. Biol. 2, 69 (2014).","journal-title":"Front. Cell Dev. Biol."},{"key":"59_CR58","doi-asserted-by":"crossref","first-page":"F560","DOI":"10.1152\/ajprenal.00569.2013","volume":"307","author":"BJ Siroky","year":"2014","unstructured":"Siroky, B. J. et al. Evidence for pericyte origin of TSC-associated renal angiomyolipomas and implications for angiotensin receptor inhibition therapy. Am. J. Physiol. Renal Physiol. 307, F560\u2013F570 (2014).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"59_CR59","volume":"8","author":"AF Goncalves","year":"2017","unstructured":"Goncalves, A. F. et al. Evidence of renal angiomyolipoma neoplastic stem cells arising from renal epithelial cells. Nat. Commun. 8, 1466 (2017).","journal-title":"Nat. Commun."},{"key":"59_CR60","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1464-410X.1994.tb16577.x","volume":"74","author":"DW Webb","year":"1994","unstructured":"Webb, D. W., Kabala, J. & Osborne, J. P. A population study of renal disease in patients with tuberous sclerosis. Br. J. Urol. 74, 151\u2013154 (1994).","journal-title":"Br. J. Urol."},{"key":"59_CR61","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s11547-015-0572-7","volume":"121","author":"A Robert","year":"2016","unstructured":"Robert, A. et al. Renal involvement in tuberous sclerosis complex with emphasis on cystic lesions. Radiol. Med. 121, 402\u2013408 (2016).","journal-title":"Radiol. Med."},{"key":"59_CR62","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/jmg.33.6.480","volume":"33","author":"JA Cook","year":"1996","unstructured":"Cook, J. A., Oliver, K., Mueller, R. F. & Sampson, J. A cross sectional study of renal involvement in tuberous sclerosis. J. Med. Genet. 33, 480\u2013484 (1996).","journal-title":"J. Med. Genet."},{"key":"59_CR63","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1016\/j.ajpath.2016.08.013","volume":"186","author":"S Ren","year":"2016","unstructured":"Ren, S. et al. Inactivation of Tsc2 in mesoderm-derived cells causes polycystic kidney lesions and impairs lung alveolarization. Am. J. Pathol. 186, 3261\u20133272 (2016).","journal-title":"Am. J. Pathol."},{"key":"59_CR64","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/ng1294-328","volume":"8","author":"PT Brook-Carter","year":"1994","unstructured":"Brook-Carter, P. T. et al. Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease.\u2014.a contiguous gene syndrome. Nat. Genet. 8, 328\u2013332 (1994).","journal-title":"Nat. Genet."},{"key":"59_CR65","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1053\/ajkd.1998.v31.pm9631851","volume":"31","author":"R Torra","year":"1998","unstructured":"Torra, R. et al. Facilitated diagnosis of the contiguous gene syndrome: tuberous sclerosis and polycystic kidneys by means of haplotype studies. Am. J. Kidney Dis. 31, 1038\u20131043 (1998).","journal-title":"Am. J. Kidney Dis."},{"key":"59_CR66","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1086\/514888","volume":"61","author":"JR Sampson","year":"1997","unstructured":"Sampson, J. R. et al. Renal cystic disease in tuberous sclerosis: role of the polycystic kidney disease 1 gene. Am. J. Hum. Genet. 61, 843\u2013851 (1997).","journal-title":"Am. J. Hum. Genet."},{"key":"59_CR67","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10786","volume":"7","author":"M Pema","year":"2016","unstructured":"Pema, M. et al. mTORC1-mediated inhibition of polycystin-1 expression drives renal cyst formation in tuberous sclerosis complex. Nat. Commun. 7, 10786 (2016).","journal-title":"Nat. Commun."},{"key":"59_CR68","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/hmg\/ddn325","volume":"18","author":"TR Hartman","year":"2009","unstructured":"Hartman, T. R. et al. The tuberous sclerosis proteins regulate formation of the primary cilium via a rapamycin-insensitive and polycystin 1-independent pathway. Hum. Mol. Genet. 18, 151\u2013163 (2009).","journal-title":"Hum. Mol. Genet."},{"key":"59_CR69","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2208::AID-CNCR21>3.0.CO;2-K","volume":"83","author":"T Al-Saleem","year":"1998","unstructured":"Al-Saleem, T. et al. Malignant tumors of the kidney, brain, and soft tissues in children and young adults with the tuberous sclerosis complex. Cancer 83, 2208\u20132216 (1998).","journal-title":"Cancer"},{"key":"59_CR70","first-page":"1201","volume":"149","author":"J Bjornsson","year":"1996","unstructured":"Bjornsson, J., Short, M. P., Kwiatkowski, D. J. & Henske, E. P. Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features. Am. J. Pathol. 149, 1201\u20131208 (1996).","journal-title":"Clinical, pathological, and genetic features. Am. J. Pathol."},{"key":"59_CR71","doi-asserted-by":"crossref","first-page":"E37","DOI":"10.1016\/j.jpedsurg.2011.06.035","volume":"46","author":"M Kubo","year":"2011","unstructured":"Kubo, M., Iwashita, K., Oyachi, N., Oyama, T. & Yamamoto, T. Two different types of infantile renal cell carcinomas associated with tuberous sclerosis. J.\u00a0Pediatr. Surg. 46, E37\u2013E41 (2011).","journal-title":"J. Pediatr. Surg."},{"key":"59_CR72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006242","volume":"12","author":"K Giannikou","year":"2016","unstructured":"Giannikou, K. et al. Whole exome sequencing identifies TSC1\/TSC2 biallelic loss as the primary and sufficient driver event for renal angiomyolipoma development. PLOS Genet. 12, e1006242 (2016).","journal-title":"PLOS Genet."},{"key":"59_CR73","doi-asserted-by":"crossref","first-page":"729","DOI":"10.4111\/kju.2010.51.10.729","volume":"51","author":"SG Kang","year":"2010","unstructured":"Kang, S. G. et al. Two different renal cell carcinomas and multiple angiomyolipomas in a patient with tuberous sclerosis. Kor. J. Urol. 51, 729\u2013732 (2010).","journal-title":"Kor. J. Urol."},{"key":"59_CR74","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/modpathol.3880275","volume":"14","author":"RE Jimenez","year":"2001","unstructured":"Jimenez, R. E. et al. Concurrent angiomyolipoma and renal cell neoplasia: a study of 36 cases. Mod. Pathol. 14, 157\u2013163 (2001).","journal-title":"Mod. Pathol."},{"key":"59_CR75","first-page":"743","volume-title":"N. Engl. J. Med.","author":"E Paul","year":"2011","unstructured":"Paul, E., Thiele, E. A., Shailam, R., Rosales, A. M. & Sadow, P. M. Case records of the Massachusetts general hospital. Case 26\u20132011. A 7-year-old boy with a complex cyst in the kidney. N. Engl. J. Med. 365, (743\u2013751 (2011)."},{"key":"59_CR76","first-page":"728","volume-title":"Clin. Kidney J.","author":"MJ Buj Pradilla","year":"2017","unstructured":"Buj Pradilla, M. J., Marti Balleste, T., Torra, R. & Villacampa Auba, F. Recommendations for imaging-based diagnosis and management of renal angiomyolipoma associated with tuberous sclerosis complex. Clin. Kidney J. 10, (728\u2013737 (2017)."},{"key":"59_CR77","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1053\/j.sult.2016.11.001","volume":"38","author":"M Jinzaki","year":"2017","unstructured":"Jinzaki, M., Silverman, S. G., Akita, H., Mikami, S. & Oya, M. Diagnosis of renal angiomyolipomas: classic, fat-poor, and epithelioid types. Semin. Ultrasound CT MR 38, 37\u201346 (2017).","journal-title":"Semin. Ultrasound CT MR"},{"key":"59_CR78","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1089\/end.2016.0219","volume":"31","author":"AM Potretzke","year":"2017","unstructured":"Potretzke, A. M. et al. Computed tomography and magnetic resonance findings of fat-poor angiomyolipomas. J. Endourol. 31, 119\u2013128 (2017).","journal-title":"J. Endourol."},{"key":"59_CR79","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000448293","volume":"134","author":"JC Kingswood","year":"2016","unstructured":"Kingswood, J. C. et al. Review of the tuberous sclerosis renal guidelines from the 2012 consensus conference: current data and future study. Nephron 134, 51\u201358 (2016).","journal-title":"Nephron"},{"key":"59_CR80","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/1756287216641353","volume":"8","author":"JJ Bissler","year":"2016","unstructured":"Bissler, J. J. & Kingswood, J. C. Optimal treatment of tuberous sclerosis complex associated renal angiomyolipomata: a systematic review. Ther. Adv. Urol. 8, 279\u2013290 (2016).","journal-title":"Ther. Adv. Urol."},{"key":"59_CR81","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1148\/radiol.2251011477","volume":"225","author":"K Yamakado","year":"2002","unstructured":"Yamakado, K. et al. Renal angiomyolipoma: relationships between tumor size, aneurysm formation, and rupture. Radiology 225, 78\u201382 (2002).","journal-title":"Radiology"},{"key":"59_CR82","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1053\/j.ajkd.2005.09.028","volume":"47","author":"JM Williams","year":"2006","unstructured":"Williams, J. M., Racadio, J. M., Johnson, N. D., Donnelly, L. F. & Bissler, J. J. Embolization of renal angiomyolipomata in patients with tuberous sclerosis complex. Am. J. Kidney Dis. 47, 95\u2013102 (2006).","journal-title":"Am. J. Kidney Dis."},{"key":"59_CR83","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00467-017-3806-1","volume":"33","author":"JJ Bissler","year":"2018","unstructured":"Bissler, J. J. et al. The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma. Pediatr. Nephrol. 33, 101\u2013109 (2018).","journal-title":"Pediatr. Nephrol."},{"key":"59_CR84","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180939","volume":"12","author":"JJ Bissler","year":"2017","unstructured":"Bissler, J. J. et al. Everolimus long-term use in patients with tuberous sclerosis complex: four-year update of the EXIST-2 study. PLOS ONE 12, e0180939 (2017).","journal-title":"PLOS ONE"},{"key":"59_CR85","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056199","volume":"8","author":"IA Malinowska","year":"2013","unstructured":"Malinowska, I. A. et al. Similar trends in serum VEGF-D levels and kidney angiomyolipoma responses with longer duration sirolimus treatment in adults with tuberous sclerosis. PLOS ONE 8, e56199 (2013).","journal-title":"PLOS ONE"},{"key":"59_CR86","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S1470-2045(14)70489-9","volume":"15","author":"DN Franz","year":"2014","unstructured":"Franz, D. N. et al. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. Lancet Oncol. 15, 1513\u20131520 (2014).","journal-title":"Lancet Oncol."},{"key":"59_CR87","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jpeds.2013.12.053","volume":"164","author":"M Cardamone","year":"2014","unstructured":"Cardamone, M. et al. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex. J. Pediatr. 164, 1195\u20131200 (2014).","journal-title":"J. Pediatr."},{"key":"59_CR88","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.pediatrneurol.2015.05.020","volume":"53","author":"S Cheng","year":"2015","unstructured":"Cheng, S., Hawkins, C., Taylor, M. D. & Bartels, U. Pathological findings of a subependymal giant cell astrocytoma following treatment with rapamycin. Pediatr. Neurol. 53, 238\u2013242 (2015).","journal-title":"Pediatr. Neurol."},{"key":"59_CR89","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1056\/NEJMc072500","volume":"358","author":"DM Davies","year":"2008","unstructured":"Davies, D. M. et al. Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N. Engl. J. Med. 358, 200\u2013203 (2008).","journal-title":"N. Engl. J. Med."},{"key":"59_CR90","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","volume":"381","author":"DN Franz","year":"2013","unstructured":"Franz, D. N. et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 381, 125\u2013132 (2013).","journal-title":"Lancet"},{"key":"59_CR91","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/ndt\/gfv249","volume":"31","author":"JJ Bissler","year":"2016","unstructured":"Bissler, J. J. et al. Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial. Nephrol. Dial. Transplant. 31, 111\u2013119 (2016).","journal-title":"Nephrol. Dial. Transplant."},{"key":"59_CR92","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189132","volume":"12","author":"S Brakemeier","year":"2017","unstructured":"Brakemeier, S. et al. Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC). PLOS ONE 12, e0189132 (2017).","journal-title":"PLOS ONE"},{"key":"59_CR93","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.2215\/CJN.08150816","volume":"12","author":"JA Samuels","year":"2017","unstructured":"Samuels, J. A. Treatment of renal angiomyolipoma and other hamartomas in patients with tuberous sclerosis complex. Clin. J. Am. Soc. Nephrol. 12, 1196\u20131202 (2017).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"59_CR94","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jvir.2016.05.029","volume":"27","author":"RA Sheth","year":"2016","unstructured":"Sheth, R. A., Feldman, A. S., Paul, E., Thiele, E. A. & Walker, T. G. Sporadic versus tuberous sclerosis complex-associated angiomyolipomas: predictors for long-term outcomes following transcatheter embolization. J. Vasc. Interv. Radiol. 27, 1542\u20131549 (2016).","journal-title":"J. Vasc. Interv. Radiol."},{"key":"59_CR95","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1053\/ajkd.2002.32770","volume":"39","author":"JJ Bissler","year":"2002","unstructured":"Bissler, J. J., Racadio, J., Donnelly, L. F. & Johnson, N. D. Reduction of postembolization syndrome after ablation of renal angiomyolipoma. Am. J. Kidney Dis. 39, 966\u2013971 (2002).","journal-title":"Am. J. Kidney Dis."},{"key":"59_CR96","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1073\/pnas.0509694103","volume":"103","author":"JM Shillingford","year":"2006","unstructured":"Shillingford, J. M. et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc. Natl Acad. Sci. USA 103, 5466\u20135471 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"59_CR97","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1093\/hmg\/ddp149","volume":"18","author":"CS Bonnet","year":"2009","unstructured":"Bonnet, C. S. et al. Defects in cell polarity underlie TSC and ADPKD-associated cystogenesis. Hum. Mol. Genet. 18, 2166\u20132176 (2009).","journal-title":"Hum. Mol. Genet."},{"key":"59_CR98","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2215\/CJN.02650313","volume":"9","author":"WE Braun","year":"2014","unstructured":"Braun, W. E., Schold, J. D., Stephany, B. R., Spirko, R. A. & Herts, B. R. Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: an open-label randomized controlled pilot study. Clin. J. Am. Soc. Nephrol. 9, 881\u2013888 (2014).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"59_CR99","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","volume":"363","author":"G Walz","year":"2010","unstructured":"Walz, G. et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 363, 830\u2013840 (2010).","journal-title":"N. Engl. J. Med."},{"key":"59_CR100","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","volume":"363","author":"AL Serra","year":"2010","unstructured":"Serra, A. L. et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N. Engl. J. Med. 363, 820\u2013829 (2010).","journal-title":"N. Engl. J. Med."},{"key":"59_CR101","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1681\/ASN.2009121302","volume":"21","author":"N Perico","year":"2010","unstructured":"Perico, N. et al. Sirolimus therapy to halt the progression of ADPKD. J. Am. Soc. Nephrol. 21, 1031\u20131040 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"59_CR102","volume":"8","author":"HS Kim","year":"2014","unstructured":"Kim, H. S. et al. The use of everolimus to target carcinogenic pathways in a patient with renal cell carcinoma and tuberous sclerosis complex: a case report. J. Med. Case Rep. 8, 95 (2014).","journal-title":"J. Med. Case Rep."},{"key":"59_CR103","doi-asserted-by":"crossref","first-page":"a002220","DOI":"10.1101\/mcs.a002220","volume":"4","author":"S Alsidawi","year":"2018","unstructured":"Alsidawi, S. & Kasi, P. M. Exceptional response to everolimus in a novel tuberous sclerosis complex-2 mutation-associated metastatic renal-cell carcinoma. Cold Spring Harb. Mol. Case Stud. 4, a002220 (2018).","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"key":"59_CR104","doi-asserted-by":"crossref","first-page":"L694","DOI":"10.1152\/ajplung.00204.2003","volume":"286","author":"J Yu","year":"2004","unstructured":"Yu, J., Astrinidis, A., Howard, S. & Henske, E. P. Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways. Am. J. Physiol. Lung Cell. Mol. Physiol. 286, L694\u2013L700 (2004).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"59_CR105","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1093\/hmg\/ddy073","volume":"27","author":"B Ogorek","year":"2018","unstructured":"Ogorek, B. et al. TSC2 regulates microRNA biogenesis via mTORC1 and GSK3\u03b2. Hum. Mol. Genet. 27, 1654\u20131663 (2018).","journal-title":"Hum. Mol. Genet."},{"key":"59_CR106","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1158\/1541-7786.MCR-13-0258-T","volume":"12","author":"AA Parkhitko","year":"2014","unstructured":"Parkhitko, A. A. et al. Autophagy-dependent metabolic reprogramming sensitizes TSC2-deficient cells to the antimetabolite 6-aminonicotinamide. Mol. Cancer Res. 12, 48\u201357 (2014).","journal-title":"Mol. Cancer Res."},{"key":"59_CR107","doi-asserted-by":"crossref","first-page":"38099","DOI":"10.18632\/oncotarget.17485","volume":"8","author":"H Filippakis","year":"2017","unstructured":"Filippakis, H. et al. Lysosomal regulation of cholesterol homeostasis in tuberous sclerosis complex is mediated via NPC1 and LDL-R. Oncotarget 8, 38099\u201338112 (2017).","journal-title":"Oncotarget"},{"key":"59_CR108","doi-asserted-by":"crossref","first-page":"98674","DOI":"10.1172\/jci.insight.98674","volume":"3","author":"HJ Liu","year":"2018","unstructured":"Liu, H. J. et al. TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1\/anti-CTLA-4 immunotherapy. JCI Insight 3, 98674 (2018).","journal-title":"JCI Insight"},{"key":"59_CR109","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.cell.2013.04.023","volume":"153","author":"A Csibi","year":"2013","unstructured":"Csibi, A. et al. The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell 153, 840\u2013854 (2013).","journal-title":"Cell"},{"key":"59_CR110","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1158\/0008-5472.CAN-16-2458","volume":"77","author":"HC Lam","year":"2017","unstructured":"Lam, H. C. et al. p62\/SQSTM1 cooperates with hyperactive mTORC1 to regulate glutathione production, maintain mitochondrial integrity, and promote tumorigenesis. Cancer Res. 77, 3255\u20133267 (2017).","journal-title":"Cancer Res."},{"key":"59_CR111","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI7319","volume":"104","author":"H Onda","year":"1999","unstructured":"Onda, H., Lueck, A., Marks, P. W., Warren, H. B. & Kwiatkowski, D. J. Tsc2\n                           +\/\u2212 mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J. Clin. Invest. 104, 687\u2013695 (1999).","journal-title":"J. Clin. Invest."},{"key":"59_CR112","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/gcc.20118","volume":"42","author":"L Lee","year":"2005","unstructured":"Lee, L. et al. Efficacy of a rapamycin analog (CCI-779) and IFN-\u03b3 in tuberous sclerosis mouse models. Genes Chromosomes Cancer 42, 213\u2013227 (2005).","journal-title":"Genes Chromosomes Cancer"},{"key":"59_CR113","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1084\/jem.20140341","volume":"211","author":"N Liang","year":"2014","unstructured":"Liang, N. et al. Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex. J. Exp. Med. 211, 2249\u20132263 (2014).","journal-title":"J. Exp. Med."},{"key":"59_CR114","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/nm.1865","volume":"14","author":"M Traykova-Brauch","year":"2008","unstructured":"Traykova-Brauch, M. et al. An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic mice. Nat. Med. 14, 979\u2013984 (2008).","journal-title":"Nat. Med."},{"key":"59_CR115","doi-asserted-by":"crossref","first-page":"4428","DOI":"10.1093\/hmg\/ddp398","volume":"18","author":"J Zhou","year":"2009","unstructured":"Zhou, J., Brugarolas, J. & Parada, L. F. Loss of Tsc1, but not Pten, in renal tubular cells causes polycystic kidney disease by activating mTORC1. Hum. Mol. Genet. 18, 4428\u20134441 (2009).","journal-title":"Hum. Mol. Genet."},{"key":"59_CR116","doi-asserted-by":"crossref","first-page":"C836","DOI":"10.1152\/ajpcell.00554.2007","volume":"295","author":"CL Buller","year":"2008","unstructured":"Buller, C. L. et al. A GSK-3\/TSC2\/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression. Am. J. Physiol. Cell Physiol. 295, C836\u2013C843 (2008).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"59_CR117","doi-asserted-by":"crossref","DOI":"10.1186\/1741-7007-9-69","volume":"9","author":"A Csibi","year":"2011","unstructured":"Csibi, A. & Blenis, J. Appetite for destruction: the inhibition of glycolysis as a therapy for tuberous sclerosis complex-related tumors. BMC Biol. 9, 69 (2011).","journal-title":"BMC Biol."},{"key":"59_CR118","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.molcel.2010.05.007","volume":"38","author":"AY Choo","year":"2010","unstructured":"Choo, A. Y. et al. Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply. Mol. Cell 38, 487\u2013499 (2010).","journal-title":"Mol. Cell"},{"key":"59_CR119","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1126\/science.1228792","volume":"339","author":"I Ben-Sahra","year":"2013","unstructured":"Ben-Sahra, I., Howell, J. J., Asara, J. M. & Manning, B. D. Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science 339, 1323\u20131328 (2013).","journal-title":"Science"},{"key":"59_CR120","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1126\/science.aad0489","volume":"351","author":"I Ben-Sahra","year":"2016","unstructured":"Ben-Sahra, I., Hoxhaj, G., Ricoult, S. J. H., Asara, J. M. & Manning, B. D. mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle. Science 351, 728\u2013733 (2016).","journal-title":"Science"},{"key":"59_CR121","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1165\/rcmb.2014-0379RC","volume":"53","author":"C Priolo","year":"2015","unstructured":"Priolo, C. et al. Tuberous sclerosis complex 2 loss increases lysophosphatidylcholine synthesis in lymphangioleiomyomatosis. Am. J. Respir. Cell. Mol. Biol. 53, 33\u201341 (2015).","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"59_CR122","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.cell.2017.10.037","volume":"171","author":"G Lee","year":"2017","unstructured":"Lee, G. et al. Post-transcriptional regulation of de novo lipogenesis by mTORC1-S6K1-SRPK2 signaling. Cell 171, 1545\u20131558 (2017).","journal-title":"Cell"},{"key":"59_CR123","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1128\/MCB.01061-10","volume":"31","author":"EA Goncharova","year":"2011","unstructured":"Goncharova, E. A. et al. mTORC2 is required for proliferation and survival of TSC2-null cells. Mol. Cell. Biol. 31, 2484\u20132498 (2011).","journal-title":"Mol. Cell. Biol."},{"key":"59_CR124","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1378\/chest.14-0758","volume":"147","author":"AM Taveira-DaSilva","year":"2015","unstructured":"Taveira-DaSilva, A. M., Jones, A. M., Julien-Williams, P. A., Stylianou, M. & Moss, J. Retrospective review of combined sirolimus and simvastatin therapy in lymphangioleiomyomatosis. Chest 147, 180\u2013187 (2015).","journal-title":"Chest"},{"key":"59_CR125","unstructured":"US National Library of Medicine. ClinicalTrials.gov. \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02061397\n                    \n                   (2017)."},{"key":"59_CR126","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1084\/jem.20131080","volume":"211","author":"C Li","year":"2014","unstructured":"Li, C. et al. Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J. Exp. Med. 211, 15\u201328 (2014).","journal-title":"J. Exp. Med."},{"key":"59_CR127","unstructured":"US National Library of Medicine. ClinicalTrials.gov. \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02484664\n                    \n                   (2018)."},{"key":"59_CR128","doi-asserted-by":"crossref","first-page":"F831","DOI":"10.1152\/ajprenal.00441.2011","volume":"303","author":"BJ Siroky","year":"2012","unstructured":"Siroky, B. J. et al. Human TSC-associated renal angiomyolipoma cells are hypersensitive to ER stress. Am. J. Physiol. Renal Physiol. 303, F831\u2013F844 (2012).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"59_CR129","doi-asserted-by":"crossref","first-page":"5926","DOI":"10.1523\/JNEUROSCI.0778-09.2009","volume":"29","author":"A Nardo Di","year":"2009","unstructured":"Di Nardo, A. et al. Tuberous sclerosis complex activity is required to control neuronal stress responses in an mTOR-dependent manner. J. Neurosci. 29, 5926\u20135937 (2009).","journal-title":"J. Neurosci."},{"key":"59_CR130","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/nature13492","volume":"513","author":"Y Zhang","year":"2014","unstructured":"Zhang, Y. et al. Coordinated regulation of protein synthesis and degradation by mTORC1. Nature 513, 440\u2013443 (2014).","journal-title":"Nature"},{"key":"59_CR131","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.cmet.2013.10.001","volume":"18","author":"M Morita","year":"2013","unstructured":"Morita, M. et al. mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. Cell Metab. 18, 698\u2013711 (2013).","journal-title":"Cell Metab."},{"key":"59_CR132","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.molcel.2017.08.013","volume":"67","author":"M Morita","year":"2017","unstructured":"Morita, M. et al. mTOR controls mitochondrial dynamics and cell survival via MTFP1. Mol. Cell. 67, 922\u2013935 (2017).","journal-title":"Mol. Cell."},{"key":"59_CR133","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.celrep.2016.09.054","volume":"17","author":"D Ebrahimi-Fakhari","year":"2016","unstructured":"Ebrahimi-Fakhari, D. et al. Impaired mitochondrial dynamics and mitophagy in neuronal models of tuberous sclerosis complex. Cell Rep. 17, 1053\u20131070 (2016).","journal-title":"Cell Rep."},{"key":"59_CR134","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nature06322","volume":"450","author":"JT Cunningham","year":"2007","unstructured":"Cunningham, J. T. et al. mTOR controls mitochondrial oxidative function through a YY1-PGC-1\u03b1 transcriptional complex. Nature 450, 736\u2013740 (2007).","journal-title":"Nature"},{"key":"59_CR135","doi-asserted-by":"crossref","first-page":"7130","DOI":"10.1158\/0008-5472.CAN-16-1052","volume":"76","author":"PT Filipczak","year":"2016","unstructured":"Filipczak, P. T. et al. TSC2 deficiency unmasks a novel necrosis pathway that is suppressed by the RIP1\/RIP3\/MLKL signaling cascade. Cancer Res. 76, 7130\u20137139 (2016).","journal-title":"Cancer Res."},{"key":"59_CR136","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1158\/1541-7786.MCR-14-0440","volume":"13","author":"D Medvetz","year":"2015","unstructured":"Medvetz, D. et al. High-throughput drug screen identifies chelerythrine as a selective inducer of death in a TSC2-null setting. Mol. Cancer Res. 13, 50\u201362 (2015).","journal-title":"Mol. Cancer Res."},{"key":"59_CR137","doi-asserted-by":"crossref","first-page":"E21","DOI":"10.1073\/pnas.1417015112","volume":"112","author":"J Li","year":"2015","unstructured":"Li, J. et al. Synthetic lethality of combined glutaminase and Hsp90 inhibition in mTORC1-driven tumor cells. Proc. Natl Acad. Sci. USA 112, E21\u2013E29 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"59_CR138","doi-asserted-by":"crossref","first-page":"48711","DOI":"10.18632\/oncotarget.16232","volume":"8","author":"EA Dunlop","year":"2017","unstructured":"Dunlop, E. A., Johnson, C. E., Wiltshire, M., Errington, R. J. & Tee, A. R. Targeting protein homeostasis with nelfinavir\/salinomycin dual therapy effectively induces death of mTORC1 hyperactive cells. Oncotarget 8, 48711\u201348724 (2017).","journal-title":"Oncotarget"},{"key":"59_CR139","doi-asserted-by":"crossref","first-page":"12455","DOI":"10.1073\/pnas.1104361108","volume":"108","author":"A Parkhitko","year":"2011","unstructured":"Parkhitko, A. et al. Tumorigenesis in tuberous sclerosis complex is autophagy and p62\/sequestosome 1 (SQSTM1)-dependent. Proc. Natl Acad. Sci. USA 108, 12455\u201312460 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"59_CR140","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.chest.2017.01.033","volume":"151","author":"S El-Chemaly","year":"2017","unstructured":"El-Chemaly, S. et al. Sirolimus and autophagy inhibition in lymphangioleiomyomatosis: results of a phase I clinical trial. Chest 151, 1302\u20131310 (2017).","journal-title":"Chest"},{"key":"59_CR141","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1165\/rcmb.2015-0022OC","volume":"53","author":"A Alayev","year":"2015","unstructured":"Alayev, A. et al. Effects of combining rapamycin and resveratrol on apoptosis and growth of TSC2-deficient xenograft tumors. Am. J. Respir. Cell. Mol. Biol. 53, 637\u2013646 (2015).","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"59_CR142","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1158\/0008-5472.CAN-16-2755","volume":"77","author":"Y Cui","year":"2017","unstructured":"Cui, Y. et al. Aberrant SYK kinase signaling is essential for tumorigenesis induced by TSC2 inactivation. Cancer Res. 77, 1492\u20131502 (2017).","journal-title":"Cancer Res."},{"key":"59_CR143","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfy063","author":"JC Kingswood","year":"2018","unstructured":"Kingswood, J. C. et al. Renal angiomyolipoma in patients with tuberous sclerosis complex: findings from the tuberous sclerosis registry to increase disease awareness. Nephrol. Dial. Transplant. \n                    https:\/\/doi.org\/10.1093\/ndt\/gfy063\n                    \n                   (2018).","journal-title":"Nephrol. Dial. Transplant."},{"key":"59_CR144","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/hmg\/11.5.525","volume":"11","author":"DJ Kwiatkowski","year":"2002","unstructured":"Kwiatkowski, D. J. et al. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum. Mol. Genet. 11, 525\u2013534 (2002).","journal-title":"Hum. Mol. Genet."},{"key":"59_CR145","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/dvg.20271","volume":"45","author":"O Hernandez","year":"2007","unstructured":"Hernandez, O., Way, S., McKenna, J. 3rd & Gambello, M. J. Generation of a conditional disruption of the Tsc2 gene. Genesis 45, 101\u2013106 (2007).","journal-title":"Genesis"},{"key":"59_CR146","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1158\/1535-7163.MCT-09-0055","volume":"8","author":"GA Finlay","year":"2009","unstructured":"Finlay, G. A., Malhowski, A. J., Polizzi, K., Malinowska-Kolodziej, I. & Kwiatkowski, D. J. Renal and liver tumors in Tsc2\n                           +\/\u2212 mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Mol. Cancer Ther. 8, 1799\u20131807 (2009).","journal-title":"Mol. Cancer Ther."},{"key":"59_CR147","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2210-9-8","volume":"9","author":"N Lee","year":"2009","unstructured":"Lee, N. et al. Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models. BMC Pharmacol. 9, 8 (2009).","journal-title":"BMC Pharmacol."},{"key":"59_CR148","doi-asserted-by":"crossref","first-page":"289.e1","DOI":"10.1016\/j.ajog.2009.10.885","volume":"202","author":"D Zhang","year":"2010","unstructured":"Zhang, D. et al. Green tea extract inhibits proliferation of uterine leiomyoma cells in vitro and in nude mice. Am. J. Obstet. Gynecol. 202, 289.e1\u2013289.e9 (2010).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"59_CR149","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1158\/0008-5472.CAN-15-2629","volume":"76","author":"J Li","year":"2016","unstructured":"Li, J. et al. mTORC1-Driven tumor cells are highly sensitive to therapeutic targeting by antagonists of oxidative stress. Cancer Res. 76, 4816\u20134827 (2016).","journal-title":"Cancer Res."},{"key":"59_CR150","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ccell.2017.09.013","volume":"32","author":"AJ Valvezan","year":"2017","unstructured":"Valvezan, A. J. et al. mTORC1 couples nucleotide synthesis to nucleotide demand resulting in a targetable metabolic vulnerability. Cancer Cell 32, 624\u2013638 (2017).","journal-title":"Cancer Cell"}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41581-018-0059-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41581-018-0059-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41581-018-0059-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T22:07:40Z","timestamp":1684620460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-018-0059-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,19]]},"references-count":150,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["59"],"URL":"https:\/\/doi.org\/10.1038\/s41581-018-0059-6","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,19]]},"assertion":[{"value":"19 September 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}